Trial · NCT03816891
Adverse events196
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 196
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Fatigue | General disorders | Phase 2a - Vixarelimab 360 mg SC QW | 0 | 23 | |
| other | Fatigue | General disorders | Phase 2a - Placebo SC QW | 0 | 26 | |
| other | Fatigue | General disorders | Phase 2b - Vixarelimab 540 mg SC Q4W (DBL) | 5 | 47 | |
| other | Fatigue | General disorders | Phase 2b - Vixarelimab 360 mg SC, Q4W (DBL) | 1 | 47 | |
| other | Fatigue | General disorders | Phase 2b - Vixarelimab 120 mg SC, Q4W (DBL) | 1 | 47 | |
| other | Fatigue | General disorders | Phase 2b - Placebo SC, Q4W (DBL) | 1 | 48 | |
| other | Fatigue | General disorders | Phase 2b - Vixarelimab 360 mg SC, Q2W (OLE Period) | 3 | 181 | |
| other | COVID-19 | Infections and infestations | Phase 2a - Vixarelimab 360 mg SC QW | 0 | 23 | |
| other | COVID-19 | Infections and infestations | Phase 2a - Placebo SC QW | 0 | 26 | |
| other | COVID-19 | Infections and infestations | Phase 2b - Vixarelimab 540 mg SC Q4W (DBL) | 3 | 47 | |
| other | COVID-19 | Infections and infestations | Phase 2b - Vixarelimab 360 mg SC, Q4W (DBL) | 1 | 47 | |
| other | COVID-19 | Infections and infestations | Phase 2b - Vixarelimab 120 mg SC, Q4W (DBL) | 0 | 47 | |
| other | COVID-19 | Infections and infestations | Phase 2b - Placebo SC, Q4W (DBL) | 4 | 48 | |
| other | COVID-19 | Infections and infestations | Phase 2b - Vixarelimab 360 mg SC, Q2W (OLE Period) | 28 | 181 | |
| other | Nasopharyngitis | Infections and infestations | Phase 2a - Vixarelimab 360 mg SC QW | 3 | 23 | |
| other | Nasopharyngitis | Infections and infestations | Phase 2a - Placebo SC QW | 4 | 26 | |
| other | Nasopharyngitis | Infections and infestations | Phase 2b - Vixarelimab 540 mg SC Q4W (DBL) | 4 | 47 | |
| other | Nasopharyngitis | Infections and infestations | Phase 2b - Vixarelimab 360 mg SC, Q4W (DBL) | 1 | 47 | |
| other | Nasopharyngitis | Infections and infestations | Phase 2b - Vixarelimab 120 mg SC, Q4W (DBL) | 1 | 47 | |
| other | Nasopharyngitis | Infections and infestations | Phase 2b - Placebo SC, Q4W (DBL) | 2 | 48 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03816891/events